Jade-Eva Potvin1, Philippe Leprohon1, Marine Queffeulou1, Shyam Sundar2, Marc Ouellette1. 1. Division of Infectious Disease and Immunity, CHU de Quebec Research Center and Department of Microbiology, Infectious Disease, and Immunology, University Laval, Quebec, Canada. 2. Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Abstract
BACKGROUND: Antimonial drugs have long been the mainstay to treat visceral leishmaniasis. Their use has been discontinued in the Indian subcontinent because of drug resistance, but they are still clinically useful elsewhere. The goal of this study was to find markers of antimony resistance in Leishmania donovani clinical isolates and validate experimentally their role in resistance. METHODS: The genomes of sensitive and antimony-resistant clinical isolates were sequenced. The role of a specific gene in contributing to resistance was studied by CRISPR-Cas9-mediated gene editing and intracellular drug sensitivity assays. RESULTS: Both gene copy number variations and single nucleotide variants were associated with antimony resistance. A homozygous insertion of 2 nucleotides was found in the gene coding for the aquaglyceroporin AQP1 in both resistant isolates. Restoring the wild-type AQP1 open reading frame re-sensitized the 2 independent resistant isolates to antimonials. Alternatively, editing the genome of a sensitive isolate by incorporating the 2-nucleotide insertion in its AQP1 gene led to antimony-resistant parasites. CONCLUSIONS: Through genomic analysis and CRISPR-Cas9-mediated genome editing we have proven the role of the AQP1 mutations in antimony clinical resistance in L. donovani.
BACKGROUND: Antimonial drugs have long been the mainstay to treat visceral leishmaniasis. Their use has been discontinued in the Indian subcontinent because of drug resistance, but they are still clinically useful elsewhere. The goal of this study was to find markers of antimony resistance in Leishmania donovani clinical isolates and validate experimentally their role in resistance. METHODS: The genomes of sensitive and antimony-resistant clinical isolates were sequenced. The role of a specific gene in contributing to resistance was studied by CRISPR-Cas9-mediated gene editing and intracellular drug sensitivity assays. RESULTS: Both gene copy number variations and single nucleotide variants were associated with antimony resistance. A homozygous insertion of 2 nucleotides was found in the gene coding for the aquaglyceroporin AQP1 in both resistant isolates. Restoring the wild-type AQP1 open reading frame re-sensitized the 2 independent resistant isolates to antimonials. Alternatively, editing the genome of a sensitive isolate by incorporating the 2-nucleotide insertion in its AQP1 gene led to antimony-resistant parasites. CONCLUSIONS: Through genomic analysis and CRISPR-Cas9-mediated genome editing we have proven the role of the AQP1 mutations in antimony clinical resistance in L. donovani.
Authors: Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo Journal: Genome Res Date: 2010-07-19 Impact factor: 9.043
Authors: G Roy; C Dumas; D Sereno; Y Wu; A K Singh; M J Tremblay; M Ouellette; M Olivier; B Papadopoulou Journal: Mol Biochem Parasitol Date: 2000-10 Impact factor: 1.759
Authors: R Mukhopadhyay; S Dey; N Xu; D Gage; J Lightbody; M Ouellette; B P Rosen Journal: Proc Natl Acad Sci U S A Date: 1996-09-17 Impact factor: 11.205
Authors: Alicia Ponte-Sucre; Francisco Gamarro; Jean-Claude Dujardin; Michael P Barrett; Rogelio López-Vélez; Raquel García-Hernández; Andrew W Pountain; Roy Mwenechanya; Barbara Papadopoulou Journal: PLoS Negl Trop Dis Date: 2017-12-14
Authors: Ana Victoria Ibarra-Meneses; Audrey Corbeil; Victoria Wagner; Francis Beaudry; Rubens L do Monte-Neto; Christopher Fernandez-Prada Journal: Front Cell Infect Microbiol Date: 2022-08-03 Impact factor: 6.073